moxifloxacin has been researched along with zithromax in 138 studies
| Studies (moxifloxacin) | Trials (moxifloxacin) | Recent Studies (post-2010) (moxifloxacin) | Studies (zithromax) | Trials (zithromax) | Recent Studies (post-2010) (zithromax) |
|---|---|---|---|---|---|
| 3,157 | 552 | 1,690 | 6,964 | 1,263 | 3,790 |
| Protein | Taxonomy | moxifloxacin (IC50) | zithromax (IC50) |
|---|---|---|---|
| 30S ribosomal protein S6 | Escherichia coli K-12 | 0.3 | |
| 30S ribosomal protein S7 | Escherichia coli K-12 | 0.3 | |
| 50S ribosomal protein L15 | Escherichia coli K-12 | 0.3 | |
| 50S ribosomal protein L10 | Escherichia coli K-12 | 0.3 | |
| 50S ribosomal protein L11 | Escherichia coli K-12 | 0.3 | |
| 50S ribosomal protein L7/L12 | Escherichia coli K-12 | 0.3 | |
| 50S ribosomal protein L19 | Escherichia coli K-12 | 0.3 | |
| 50S ribosomal protein L1 | Escherichia coli K-12 | 0.3 | |
| 50S ribosomal protein L20 | Escherichia coli K-12 | 0.3 | |
| 50S ribosomal protein L27 | Escherichia coli K-12 | 0.3 | |
| 50S ribosomal protein L28 | Escherichia coli K-12 | 0.3 | |
| 50S ribosomal protein L29 | Escherichia coli K-12 | 0.3 | |
| 50S ribosomal protein L31 | Escherichia coli K-12 | 0.3 | |
| 50S ribosomal protein L31 type B | Escherichia coli K-12 | 0.3 | |
| 50S ribosomal protein L32 | Escherichia coli K-12 | 0.3 | |
| 50S ribosomal protein L33 | Escherichia coli K-12 | 0.3 | |
| 50S ribosomal protein L34 | Escherichia coli K-12 | 0.3 | |
| 50S ribosomal protein L35 | Escherichia coli K-12 | 0.3 | |
| 50S ribosomal protein L36 | Escherichia coli K-12 | 0.3 | |
| 30S ribosomal protein S10 | Escherichia coli K-12 | 0.3 | |
| 30S ribosomal protein S11 | Escherichia coli K-12 | 0.3 | |
| 30S ribosomal protein S12 | Escherichia coli K-12 | 0.3 | |
| 30S ribosomal protein S13 | Escherichia coli K-12 | 0.3 | |
| 30S ribosomal protein S16 | Escherichia coli K-12 | 0.3 | |
| 30S ribosomal protein S18 | Escherichia coli K-12 | 0.3 | |
| 30S ribosomal protein S19 | Escherichia coli K-12 | 0.3 | |
| 30S ribosomal protein S20 | Escherichia coli K-12 | 0.3 | |
| 30S ribosomal protein S2 | Escherichia coli K-12 | 0.3 | |
| 30S ribosomal protein S3 | Escherichia coli K-12 | 0.3 | |
| 30S ribosomal protein S4 | Escherichia coli K-12 | 0.3 | |
| 30S ribosomal protein S5 | Escherichia coli K-12 | 0.3 | |
| 30S ribosomal protein S8 | Escherichia coli K-12 | 0.3 | |
| 30S ribosomal protein S9 | Escherichia coli K-12 | 0.3 | |
| 50S ribosomal protein L13 | Escherichia coli K-12 | 0.3 | |
| 50S ribosomal protein L14 | Escherichia coli K-12 | 0.3 | |
| 50S ribosomal protein L16 | Escherichia coli K-12 | 0.3 | |
| 50S ribosomal protein L23 | Escherichia coli K-12 | 0.3 | |
| 30S ribosomal protein S15 | Escherichia coli K-12 | 0.3 | |
| 50S ribosomal protein L17 | Escherichia coli K-12 | 0.3 | |
| 50S ribosomal protein L21 | Escherichia coli K-12 | 0.3 | |
| 50S ribosomal protein L30 | Escherichia coli K-12 | 0.3 | |
| 50S ribosomal protein L6 | Escherichia coli K-12 | 0.3 | |
| 30S ribosomal protein S14 | Escherichia coli K-12 | 0.3 | |
| 30S ribosomal protein S17 | Escherichia coli K-12 | 0.3 | |
| 30S ribosomal protein S1 | Escherichia coli K-12 | 0.3 | |
| 50S ribosomal protein L18 | Escherichia coli K-12 | 0.3 | |
| 50S ribosomal protein L2 | Escherichia coli K-12 | 0.3 | |
| 50S ribosomal protein L3 | Escherichia coli K-12 | 0.3 | |
| 50S ribosomal protein L24 | Escherichia coli K-12 | 0.3 | |
| 50S ribosomal protein L4 | Escherichia coli K-12 | 0.3 | |
| 50S ribosomal protein L22 | Escherichia coli K-12 | 0.3 | |
| 50S ribosomal protein L5 | Escherichia coli K-12 | 0.3 | |
| 30S ribosomal protein S21 | Escherichia coli K-12 | 0.3 | |
| 50S ribosomal protein L25 | Escherichia coli K-12 | 0.3 | |
| 50S ribosomal protein L36 2 | Escherichia coli K-12 | 0.3 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (0.72) | 18.2507 |
| 2000's | 58 (42.03) | 29.6817 |
| 2010's | 61 (44.20) | 24.3611 |
| 2020's | 18 (13.04) | 2.80 |
| Authors | Studies |
|---|---|
| Jolivette, LJ; Nagilla, R; Ward, KW | 1 |
| Duewelhenke, N; Eysel, P; Krut, O | 1 |
| Appelbaum, PC; Credito, KL; DeWasse, B; Kosowska-Shick, K; McGhee, P; Pankuch, GA | 1 |
| Bradbury, BJ; Buechter, DD; Cheng, J; Deshpande, M; Mushtaq, G; Podos, SD; Pucci, MJ; Thanassi, JA; Thoma, CL; Vigliotti, GA | 1 |
| Bryk, A; Kanervo-Nordström, A; Könönen, E; Niemi, P | 1 |
| Ardanuy, C; Bouza, E; Calatayud, L; Cercenado, E; Fenoll, A; Liñares, J; Martín, R; Pallares, R | 1 |
| Appelbaum, PC; Clark, CL; Ednie, LM; Kosowska-Shick, K | 1 |
| Appelbaum, PC; Bogdanovich, T; Clark, C; Dewasse, B; Ednie, L; McGhee, P; Smith, K | 1 |
| Brémont, S; Courvalin, P; Damier-Piolle, L; Lambert, T; Magnet, S | 1 |
| Beckius, ML; Fraser, SL; Galloway, RL; Griffith, ME; Hospenthal, DR; Mende, K; Miller, RS; Murray, CK; Pimentel, G; Ressner, RA | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Crabb, DM; Duffy, LB; Waites, KB | 1 |
| Bohnert, JA; Fähnrich, E; Kern, WV; Schuster, S; Wehmeier, C | 1 |
| Li, W; Liu, Y; Wang, M; Xu, X; Ye, X; Zhang, H; Zhu, D | 1 |
| Appelbaum, PC; Ednie, LM; Kosowska-Shick, K; McGhee, P | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Brunner, LS; Haas, W; Lee, JC; Morris, TW; Pillar, CM; Zurenko, GE | 1 |
| Ekambaram, R; Raghunathan, M; Raghunathan, R; Rao, SS | 1 |
| Hamasuna, R; Jensen, JS; Osada, Y | 1 |
| Appelbaum, PC; Beachel, L; Clark, C; Dewasse, B; Kosowska-Shick, KM; McGhee, P; Nagai, K | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Hakanen, AJ; Huovinen, P; Kotilainen, P; Lehtopolku, M; Nakari, UM; Siitonen, A | 1 |
| Cai, L; Gilbert, GL; Kong, F; Oftadeh, S; Xiao, M; Xu, X; Zhou, F | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Inagaki, H; Kitamura, T; Komoriya, S; Kuroyanagi, J; Miyauchi, RN; Nagamochi, M; Odagiri, T; Sugimoto, Y; Takahashi, H | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Cevenini, R; D'Apote, L; Donati, M; Olmo, A; Rodrìguez Fermepin, M | 1 |
| Coleman, EJ; Mandell, GL | 2 |
| Aralar, P; Bermudez, LE; Inderlied, CB; Kolonoski, P; Petrofsky, M; Wu, M; Young, LS | 1 |
| Church, D; DeAbate, CA; Heyd, A; Mathew, CP; Warner, JH | 1 |
| Amábile-Cuevas, CF; Hermida-Escobedo, C; Vivar, R | 1 |
| Carryn, S; Mingeot-Leclercq, MP; Tulkens, PM; Van Bambeke, F | 2 |
| Seral, C; Tulkens, PM; Van Bambeke, F | 1 |
| Braman, S; Capitano, B; Mattoes, HM; Nicolau, DP; O'Brien, A; Shore, E; Sutherland, C | 1 |
| Choo, CM; Lim, T; Lim, YS; Ngan, CC; Toh, GL | 1 |
| Daschner, F; Schmidt-Eisenlohr, E; Wenzler, S | 1 |
| Bittner, T; Brade, V; Cinatl, J; Hunfeld, KP; Rödel, R | 1 |
| Alou, L; Cafini, F; Prieto, J; Sevillano, D; Valero, E | 1 |
| Choudhri, S; Fogarty, CM; Hamed, K; Katz, E; Larsen, LS; Song, J | 1 |
| Bermudez, LE; Carter, G; Young, LS | 1 |
| De Vecchi, E; Drago, L; Legnani, D; Nicola, L; Prenna, M; Ripa, S | 1 |
| Albers, C; Dalhoff, A; Döring, G; Korfmann, G; Künkele, F; Möller, JG; Ulrich, M | 1 |
| Anzueto, A; Choudhri, S; Haverstock, D; Kureishi, A; Niederman, MS; Perroncel, R; Sethi, S | 1 |
| Blair, C; Kirtsreesakul, V; Luxameechanporn, T; Naclerio, RM; Thompson, K | 1 |
| Lück, PC; Steinert, M | 1 |
| Appelbaum, PC; Bogdanovich, T; Clark, C; Ednie, L; Lin, G; Shapiro, S; Smith, K | 1 |
| Appelbaum, PC; Bozdogan, B; Choi, DR; Credito, K; Dewasse, B; Kosowska-Shick, K; Lin, G; McGhee, P; Pankuch, GA; Ryu, JM | 1 |
| Aguilar, L; Alou, L; Cafini, F; Echeverría, O; Giménez, MJ; Pérez-Trallero, E; Prieto, J; Sevillano, D | 1 |
| Bradshaw, CS; Fairley, CK; Garland, SM; Hopkins, CA; Jensen, JS; Moss, LM; Read, TR; Tabrizi, SN | 1 |
| Hand, DL; Hand, WL; Vasquez, Y | 1 |
| Blau, H; Fabian, I; Halperin, D; Klein, K; Shalit, I | 1 |
| Attevelt, NJ; Beekman, JD; Chiba, K; Sugiyama, A; Takahara, A; Thomsen, MB; Vos, MA | 1 |
| Liu, H; Liu, J; Xiong, S; Xiong, W; Xu, S; Xu, Y; Zhao, J | 1 |
| Amsden, GW; Martinez, FJ; Rothermel, CD; Treadway, G; Zervos, M | 1 |
| Haggerty, CL; Ness, RB | 1 |
| Adachi, J; Ghanem, G; Han, XY; Raad, I | 1 |
| Al-Nawas, B; Callaway, A; Geibel, MA; Karbach, J; Wagner, W; Willershausen, B | 1 |
| Buxbaum, A; Georgopoulos, A; Graninger, W; Kratzer, C; Macfelda, K | 1 |
| Conners, GP; Hays, DP | 1 |
| Girgis, D; Kabat, A; O'Brien, T; Ohnsman, C; Ritterband, D | 1 |
| Alvarez, M; Diz, P; Limeres, J; Potel, C; Tomás, I; Tomás, M; Velasco, D | 1 |
| Jernberg, E; Moghaddam, A; Moi, H | 1 |
| O'Brien, TP; Torkildsen, G | 1 |
| Dugar, M; Rankin, WA; Rowe, E; Smith, MD | 1 |
| Bhattacharya, B; Habr, F; Manlolo, J; Robinson, W | 1 |
| Brubaker, K; Crean, CS; Haque, RM; Hwang, DG; Stewart, WC; Zink, RC | 1 |
| Gieffers, J; Rupp, J; Shima, K; Solbach, W; Szaszák, M | 1 |
| Al-Nawas, B; d'Hoedt, B; Karbach, J; Mouratidou, A | 1 |
| Kim, SJ; Toma, HS | 1 |
| Culton, DA; Groben, P; Miller, M; Morrell, DS; Wertman, R | 1 |
| Baik, GH; Jung, HC; Kim, GH; Kim, HB; Kim, JM; Kim, JY; Kim, NY; Kim, SJ; Lee, DH; Nam, RH; Song, IS | 1 |
| Dan, M; Rosenberg, S; Samra, Z | 1 |
| Dave, SB; Kim, SJ; Toma, HS | 2 |
| Izumi, K; Mikamo, H; Ohki, E; Terada, M; Yamagishi, Y | 1 |
| Broad, JM; Golden, MR; Manhart, LE | 1 |
| Stiles, BG; Weinstein, SA | 1 |
| Deguchi, T; Hagiwara, N; Ito, S; Maeda, S; Yasuda, M | 1 |
| Blanco, AR; Papa, V; Spoto, CG; Sudano Roccaro, A | 1 |
| Hui, CK | 1 |
| Al-Nawas, B; Callaway, AS; Karbach, J; Wagner, W; Willershausen, B | 1 |
| Caballero, E; Herrmann, B; Isaksson, J; Sallés, B; Vall-Mayans, M | 1 |
| Herath, SC; Poole, P | 1 |
| Fernandes, P; Jensen, JS; Unemo, M | 1 |
| Goldstein, RC; Husk, G; Jodlowski, T; Mildvan, D; Perlman, DC; Ruhe, JJ | 1 |
| Borggren, M; Nygart, JF; Nygart, VA; Tvede, M | 1 |
| Taylor-Robinson, D | 1 |
| Elkington, PT; Friedland, JS; Gardiner, H; Kubler, A; Prasad, R; Singh, A; Singh, S; Singh, UK | 1 |
| Chan, KA; Chang, CH; Chou, HW; Lai, CL; Lai, MS; Wang, JL | 1 |
| Abdo, H; Bissessor, M; Bradshaw, CS; Chen, MY; Fairley, CK; Garland, SM; Hocking, JS; Jensen, JS; Tabrizi, SN; Twin, J; Vodstrcil, LA | 1 |
| Haugstvedt, A; Jensen, JS; Moi, H | 1 |
| Waag, DM | 1 |
| Amoroso, A; Britt, EJ; Burke, AP; Franco, M; Reed, RM | 1 |
| Mattappallil, A; Mergenhagen, KA; Ott, MC; Ruh, CA; Schroeck, JL; Sellick, JA | 1 |
| Blee, K; Evans, C; Horner, P; Muir, P; O'Mahony, C; Radcliffe, K | 1 |
| Allinson, JP; Brill, SE; Calverley, PM; Cookson, WO; Donaldson, GC; El-Emir, E; Hurst, JR; James, P; Law, M; Maddox, V; McHugh, TD; Moffatt, MF; Nazareth, I; Sweeting, MJ; Wedzicha, JA | 1 |
| Blee, K; Horner, PJ; Moi, H | 1 |
| Enger, M; Falk, L; Jensen, JS | 1 |
| Bradshaw, C; Jensen, JS | 1 |
| Brown-Elliott, BA; Chao, AS; Chiu, CH; Griffith, DE; Leu, HS; Lin, CS; Wu, TL; Wu, TS; Yang, CH | 1 |
| Blee, K; Falk, L; Horner, PJ; Moi, H; van der Meijden, W | 1 |
| Allen, V; Gesink, D; Greer, J; Jamieson, H; Jensen, JS; Juzkiw, J; Mitterni, L; Racey, CS; Seah, C; Singh, S; Zittermann, S | 1 |
| Alcaraz, I; Bertolotti, A; Derancourt, C; Dupin, N; Janier, M; Milpied, B | 1 |
| Crabb, DM; Duffy, LB; Jensen, JS; Liu, Y; Paukner, S; Waites, KB | 1 |
| Bellon, H; Heigl, T; Hoet, P; Lammertyn, E; Mathyssen, C; Pilette, C; Sacreas, A; Vanaudenaerde, BM; Vandermeulen, E; Verleden, GM; Verleden, SE; Vos, R; Vriens, H | 1 |
| Jo, KW; Nam, GB; Shim, TS; Yoon, HY | 1 |
| Deshpande, D; Gumbo, T; Sherman, CM; Srivastava, S | 1 |
| Hardin, JW; Hyche, S; Magagnoli, J; Sutton, SS | 1 |
| Guo, Y; Hu, Y; Huang, Y; Liu, D; Lu, B; Wang, X; Zhu, Z | 1 |
| Peyrusson, F; Tulkens, PM; Van Bambeke, F | 1 |
| Aung, E; Bradshaw, CS; Chen, MY; Chow, EPF; Fairley, CK; Garland, SM; Murray, G; Ong, JJ; Read, TRH | 1 |
| Liu, J; Long, X; Luo, H; Pan, X; Shen, F; Wang, S; Wu, J; Yao, L; Yuan, T | 1 |
| Herath, SC; Maisey, S; Normansell, R; Poole, P | 1 |
| Hammerschlag, MR; Huerta, N; Kohlhoff, SA | 1 |
| Auguste, U; Labbé, AC; Singh, AE | 1 |
| Macía, M; Navarro, D; Romay, AB; Trastoy, R; Treviño, M; Veiga, E | 1 |
| Grzybowski, A; Kanclerz, P | 1 |
| Aguirre, I; Bradshaw, CS; Chen, MY; Chow, EPF; Doyle, M; Durukan, D; Fairley, CK; Mokany, E; Murray, G; Read, TRH; Tan, LY; Vodstrcil, LA | 1 |
| Fernández, J; Vazquez, F | 1 |
| Cross, ELA; Hassan-Ibrahim, MO; Ovens, KJ; Reynolds-Wright, JJ; Rickwood, L; Soni, S | 1 |
| Braam, JF; Kusters, JG; van der Schalk, TE | 1 |
| Bradshaw, CS; Chow, EPF; Fairley, CK; Garland, SM; Hocking, JS; Jensen, JS; Low, N; Machalek, DA; Murray, G; Shilling, H; Tao, Y; Unemo, M; Vodstrcil, LA; Zhang, L | 1 |
| Barrientos-Durán, A; Chueca, N; de Salazar, A; Espadafor, B; Fuentes-López, A; Garcia, F | 1 |
| Ke, W; Yang, L | 1 |
| Allen, GP; Deao, KM; Hill, SA; Schipelliti, SM; Tran, T | 1 |
| Bodiyabadu, K; Bradshaw, CS; Chow, EPF; Doyle, M; Fairley, CK; Jensen, JS; Murray, GL; Plummer, EL; Sweeney, E; Vodstrcil, LA; Whiley, D; Williamson, DA | 1 |
| Cusini, M; Gomberg, M; Jensen, JS; Moi, H; Unemo, M; Wilson, J | 1 |
| Lu, D; Luo, Z; Qian, J; Wang, C; Wang, T; Ye, F; Zhang, J | 1 |
| Ishikawa, T; Kitaya, K; Sakuraba, Y; Tanaka, SE | 1 |
| Bykov, K; Fischer, MA; Gagne, JJ; Kattinakere-Sreedhara, S; Wang, J | 1 |
| Martínez Jordán, J; Moreno-Docón, A; Trueba Argamasilla, AA | 1 |
| Carelli, M; Cordioli, M; De Grandi, G; Lleo, MM; Mirandola, M; Sandri, A; Savoldi, A; Signoretto, C; Visentin, A | 1 |
| He, YS; Ji, J; Liu, G; Qian, SY; Yang, M | 1 |
| Bulychev, VV; Bulycheva, EV; Pashkova, NA | 1 |
| Aral, M; Ates, S; Doganer, A; Nazik, S; Orak, F; Yalcinkaya, KT | 1 |
13 review(s) available for moxifloxacin and zithromax
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Eradication of H. influenzae in AECB: A pooled analysis of moxifloxacin phase III trials compared with macrolide agents.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Aza Compounds; Azithromycin; Bronchitis, Chronic; Chronic Disease; Clarithromycin; Clinical Trials, Phase III as Topic; Double-Blind Method; Female; Fluoroquinolones; Haemophilus Infections; Haemophilus influenzae; Humans; Male; Middle Aged; Moxifloxacin; Multicenter Studies as Topic; Quinolines; Randomized Controlled Trials as Topic; Treatment Outcome | 2006 |
[Pathogenesis, diagnosis and therapy of Legionella infections].
Topics: Anti-Bacterial Agents; Antibodies, Bacterial; Antigens, Bacterial; Aza Compounds; Azithromycin; Ciprofloxacin; Diagnosis, Differential; DNA, Bacterial; Fluoroquinolones; Humans; Incidence; Legionella; Legionella pneumophila; Legionellosis; Legionnaires' Disease; Levofloxacin; Moxifloxacin; Ofloxacin; Polymerase Chain Reaction; Quinolines; Serotyping; Virulence | 2006 |
Newest approaches to treatment of pelvic inflammatory disease: a review of recent randomized clinical trials.
Topics: Anti-Bacterial Agents; Aza Compounds; Azithromycin; Ciprofloxacin; Clindamycin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Microbial; Female; Fluoroquinolones; Follow-Up Studies; Humans; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Pelvic Inflammatory Disease; Quinolines; Randomized Controlled Trials as Topic; Risk Assessment; Severity of Illness Index; Treatment Outcome | 2007 |
Recent perspectives in the diagnosis and evidence-based treatment of Mycoplasma genitalium.
Topics: Anti-Bacterial Agents; Aza Compounds; Azithromycin; Drug Resistance, Bacterial; Evidence-Based Medicine; Female; Fluoroquinolones; Humans; Male; Moxifloxacin; Mycoplasma genitalium; Mycoplasma Infections; Quinolines; Urethritis; Uterine Cervicitis | 2012 |
Antimicrobial chemotherapy of Mycoplasma genitalium-positive non-gonococcal urethritis.
Topics: Anti-Infective Agents; Aza Compounds; Azithromycin; Doxycycline; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Male; Moxifloxacin; Mycoplasma genitalium; Mycoplasma Infections; Quinolines; Treatment Outcome; Urethritis | 2012 |
Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD).
Topics: Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Aza Compounds; Azithromycin; Clarithromycin; Disease Progression; Erythromycin; Fluoroquinolones; Humans; Moxifloxacin; Pulmonary Disease, Chronic Obstructive; Quality of Life; Quinolines; Randomized Controlled Trials as Topic | 2013 |
Management of non-gonococcal urethritis.
Topics: Anti-Bacterial Agents; Azithromycin; Chlamydia trachomatis; Doxycycline; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Metronidazole; Moxifloxacin; Mycoplasma genitalium; Urethritis | 2015 |
Management of Mycoplasma genitalium infections - can we hit a moving target?
Topics: Anti-Bacterial Agents; Azithromycin; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Moxifloxacin; Mycoplasma genitalium; Mycoplasma Infections; Treatment Failure | 2015 |
Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD).
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Antibiotic Prophylaxis; Aza Compounds; Azithromycin; Clarithromycin; Clavulanic Acid; Disease Progression; Drug Administration Schedule; Erythromycin; Fluoroquinolones; Humans; Moxifloxacin; Pulmonary Disease, Chronic Obstructive; Quality of Life; Quinolines; Randomized Controlled Trials as Topic; Roxithromycin; Trimethoprim, Sulfamethoxazole Drug Combination | 2018 |
Molecular basis of antimicrobial resistance in Mycoplasma genitalium.
Topics: Anti-Bacterial Agents; Azithromycin; Doxycycline; Drug Resistance, Bacterial; Female; Female Urogenital Diseases; Humans; Male; Male Urogenital Diseases; Microbial Sensitivity Tests; Moxifloxacin; Mycoplasma genitalium; Mycoplasma Infections; Polymorphism, Single Nucleotide; Sexually Transmitted Diseases, Bacterial | 2020 |
Prevalence of mutations associated with resistance to macrolides and fluoroquinolones in Mycoplasma genitalium: a systematic review and meta-analysis.
Topics: Anti-Bacterial Agents; Azithromycin; Carrier Proteins; Drug Resistance, Bacterial; Female; Humans; Male; Moxifloxacin; Mutation; Mycoplasma genitalium; Mycoplasma Infections; Polymorphism, Single Nucleotide; Prevalence; RNA, Ribosomal, 23S; Sexually Transmitted Diseases, Bacterial; Transferases | 2020 |
Evaluation of the Therapeutic Effect of Antibiotics on Scrub Typhus: A Systematic Review and Network Meta-Analysis.
Topics: Anti-Bacterial Agents; Azithromycin; Child; Chloramphenicol; Female; Humans; Moxifloxacin; Network Meta-Analysis; Rifampin; Scrub Typhus | 2022 |
15 trial(s) available for moxifloxacin and zithromax
| Article | Year |
|---|---|
The safety and efficacy of short course (5-day) moxifloxacin vs. azithromycin in the treatment of patients with acute exacerbation of chronic bronchitis.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Azithromycin; Bacterial Infections; Bronchitis; Chronic Disease; Double-Blind Method; Female; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Multicenter Studies as Topic; Prospective Studies; Quinolines | 2000 |
Steady-state intrapulmonary concentrations of moxifloxacin, levofloxacin, and azithromycin in older adults.
Topics: Aged; Anti-Bacterial Agents; Area Under Curve; Aza Compounds; Azithromycin; Bronchoalveolar Lavage Fluid; Extravascular Lung Water; Female; Fluoroquinolones; Humans; Levofloxacin; Lung; Macrophages, Alveolar; Male; Middle Aged; Moxifloxacin; Ofloxacin; Quinolines; Urea | 2004 |
Safety and efficacy of sequential i.v. to p.o. moxifloxacin versus conventional combination therapies for the treatment of community-acquired pneumonia in patients requiring initial i.v. therapy.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Aza Compounds; Azithromycin; Ceftriaxone; Community-Acquired Infections; Constipation; Drug Therapy, Combination; Emergency Medical Services; Female; Fluoroquinolones; Humans; Male; Metronidazole; Middle Aged; Moxifloxacin; Nausea; Pneumonia, Bacterial; Prospective Studies; Quinolines; Safety; Time Factors; Treatment Outcome | 2004 |
Efficacy and safety of intravenous moxifloxacin versus cefoperazone with azithromycin in the treatment of community acquired pneumonia.
Topics: Adolescent; Adult; Anti-Infective Agents; Aza Compounds; Azithromycin; Cefoperazone; Community-Acquired Infections; Female; Fluoroquinolones; Humans; Infusions, Intravenous; Male; Middle Aged; Moxifloxacin; Pneumonia, Bacterial; Quinolines; Treatment Outcome | 2006 |
Efficacy and safety of 3-day azithromycin versus 5-day moxifloxacin for the treatment of acute bacterial exacerbations of chronic bronchitis.
Topics: Abdominal Pain; Adult; Aged; Anti-Bacterial Agents; Aza Compounds; Azithromycin; Bronchitis, Chronic; Drug Administration Schedule; Female; Fluoroquinolones; Haemophilus influenzae; Haemophilus parainfluenzae; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Moraxella catarrhalis; Moxifloxacin; Nausea; Patient Compliance; Quinolines; Single-Blind Method; Streptococcus pneumoniae; Treatment Outcome; Vaginitis | 2007 |
Comparison of azithromycin and moxifloxacin against bacterial isolates causing conjunctivitis.
Topics: Anti-Bacterial Agents; Aza Compounds; Azithromycin; Conjunctivitis, Bacterial; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Moxifloxacin; Quinolines | 2007 |
Conjunctival tissue pharmacokinetic properties of topical azithromycin 1% and moxifloxacin 0.5% ophthalmic solutions: a single-dose, randomized, open-label, active-controlled trial in healthy adult volunteers.
Topics: Adult; Anti-Bacterial Agents; Area Under Curve; Aza Compounds; Azithromycin; Chromatography, Liquid; Conjunctiva; Dizziness; Eye Hemorrhage; Female; Fluoroquinolones; Half-Life; Humans; Male; Moxifloxacin; Ophthalmic Solutions; Quinolines; Tandem Mass Spectrometry; Tissue Distribution | 2008 |
Pharmacokinetics of azithromycin and moxifloxacin in human conjunctiva and aqueous humor during and after the approved dosing regimens.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Aqueous Humor; Aza Compounds; Azithromycin; Biological Availability; Cataract Extraction; Chromatography, High Pressure Liquid; Conjunctiva; Female; Fluoroquinolones; Half-Life; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Quinolines; Tandem Mass Spectrometry | 2010 |
Ophthalmic antibiotics and antimicrobial resistance a randomized, controlled study of patients undergoing intravitreal injections.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Aza Compounds; Azithromycin; Conjunctiva; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Intravitreal Injections; Levofloxacin; Middle Aged; Moxifloxacin; Nasopharynx; Ofloxacin; Prospective Studies; Quinolines; Staphylococcal Infections | 2011 |
Ophthalmic antibiotic use and multidrug-resistant staphylococcus epidermidis: a controlled, longitudinal study.
Topics: Adult; Anti-Bacterial Agents; Aza Compounds; Azithromycin; Choroidal Neovascularization; Conjunctiva; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Follow-Up Studies; Gatifloxacin; Humans; Intravitreal Injections; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Prospective Studies; Quinolines; Staphylococcus epidermidis; Young Adult | 2011 |
Changes in ocular flora in eyes exposed to ophthalmic antibiotics.
Topics: Adult; Anti-Bacterial Agents; Aza Compounds; Azithromycin; Bacteria; Choroidal Neovascularization; Conjunctiva; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Intravitreal Injections; Longitudinal Studies; Moxifloxacin; Ofloxacin; Quinolines | 2013 |
Effects of different antibiotic classes on airway bacteria in stable COPD using culture and molecular techniques: a randomised controlled trial.
Topics: Aged; Anti-Bacterial Agents; Azithromycin; Bacterial Load; Doxycycline; Female; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Outcome Assessment, Health Care; Pulmonary Disease, Chronic Obstructive; Respiratory System; Single-Blind Method; Sputum | 2015 |
Time to eradication of Mycoplasma genitalium after antibiotic treatment in men and women.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Azithromycin; DNA, Bacterial; DNA, Ribosomal; Drug Resistance, Bacterial; Female; Fluoroquinolones; Humans; Longitudinal Studies; Macrolides; Male; Middle Aged; Moxifloxacin; Mycoplasma genitalium; Mycoplasma Infections; Polymerase Chain Reaction; Prospective Studies; RNA, Ribosomal, 23S; Time Factors; Treatment Outcome; Urine; Vagina; Young Adult | 2015 |
[No long-term effect on pathogen load].
Topics: Azithromycin; Bacterial Load; Doxycycline; Fluoroquinolones; Humans; Moxifloxacin; Pulmonary Disease, Chronic Obstructive; Sputum | 2015 |
Multi-drug-resistant chronic endometritis in infertile women with repeated implantation failure: trend over the decade and pilot study for third-line oral antibiotic treatment.
Topics: Anti-Bacterial Agents; Azithromycin; Chronic Disease; Embryo Implantation; Endometritis; Endometrium; Female; Humans; Infertility, Female; Moxifloxacin; Pharmaceutical Preparations; Pilot Projects; Prospective Studies; Retrospective Studies | 2022 |
110 other study(ies) available for moxifloxacin and zithromax
| Article | Year |
|---|---|
Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.
Topics: Administration, Oral; Animals; Area Under Curve; Dogs; Haplorhini; Humans; Models, Statistical; Rats; Software; Species Specificity; Xenobiotics | 2005 |
Influence on mitochondria and cytotoxicity of different antibiotics administered in high concentrations on primary human osteoblasts and cell lines.
Topics: Acetamides; Aminoglycosides; Anti-Bacterial Agents; Antimycin A; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cells, Cultured; Chloramphenicol; Clindamycin; Dose-Response Relationship, Drug; Fluoroquinolones; Glycolysis; HeLa Cells; Humans; Lactic Acid; Linezolid; Macrolides; Mitochondria; Osteoblasts; Oxazolidinones; Rotenone; Tetracyclines; Time Factors | 2007 |
Multistep resistance selection and postantibiotic-effect studies of the antipneumococcal activity of LBM415 compared to other agents.
Topics: Amidohydrolases; Drug Resistance, Bacterial; Microbial Sensitivity Tests; Peptides; Pneumococcal Infections; Species Specificity; Streptococcus pneumoniae; Time Factors | 2007 |
In vitro and in vivo antibacterial activities of heteroaryl isothiazolones against resistant gram-positive pathogens.
Topics: Animals; Anti-Infective Agents; Drug Resistance, Bacterial; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Mice; Microbial Sensitivity Tests; Quinolones; Thiazoles | 2007 |
Antimicrobial susceptibilities of Peptostreptococcus anaerobius and the newly described Peptostreptococcus stomatis isolated from various human sources.
Topics: Anaerobiosis; Anti-Bacterial Agents; Bacteremia; Gram-Positive Bacterial Infections; Humans; Microbial Sensitivity Tests; Peptostreptococcus; Species Specificity | 2007 |
Serotypes, Clones, and Mechanisms of Resistance of Erythromycin-Resistant Streptococcus pneumoniae Isolates Collected in Spain.
Topics: Anti-Bacterial Agents; Clone Cells; Drug Resistance, Multiple, Bacterial; Electrophoresis, Polyacrylamide Gel; Erythromycin; Genes, Bacterial; Microbial Sensitivity Tests; Phenotype; Pneumococcal Infections; Serotyping; Spain; Streptococcus pneumoniae; Tetracycline Resistance | 2007 |
Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.
Topics: Anti-Bacterial Agents; Aza Compounds; Azithromycin; Clarithromycin; Clavulanic Acid; Clindamycin; Drug Resistance, Bacterial; Fluoroquinolones; Gemifloxacin; Imipenem; Ketolides; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines; Streptococcus pneumoniae | 2007 |
In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Culture Media; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Mutation; Streptococcus pneumoniae | 2008 |
AdeIJK, a resistance-nodulation-cell division pump effluxing multiple antibiotics in Acinetobacter baumannii.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Bacterial Proteins; Cloning, Molecular; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Humans; Membrane Transport Proteins; Microbial Sensitivity Tests; Molecular Sequence Data; Multigene Family; Sequence Analysis, DNA; Substrate Specificity | 2008 |
Antimicrobial susceptibilities of geographically diverse clinical human isolates of Leptospira.
Topics: Ampicillin; Anti-Bacterial Agents; Azithromycin; Cefepime; Cefotaxime; Ceftriaxone; Cephalosporins; Ciprofloxacin; Egypt; Hawaii; Humans; Leptospira; Leptospirosis; Levofloxacin; Microbial Sensitivity Tests; Nicaragua; Ofloxacin; Tetracycline; Thailand | 2008 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Comparative in vitro activities of the investigational fluoroquinolone DC-159a and other antimicrobial agents against human mycoplasmas and ureaplasmas.
Topics: Aminopyridines; Anti-Bacterial Agents; Fluoroquinolones; Humans; In Vitro Techniques; Microbial Sensitivity Tests; Mycoplasma; Mycoplasma fermentans; Mycoplasma genitalium; Mycoplasma hominis; Mycoplasma Infections; Mycoplasma pneumoniae; Ureaplasma; Ureaplasma Infections | 2008 |
Site-directed mutagenesis reveals amino acid residues in the Escherichia coli RND efflux pump AcrB that confer macrolide resistance.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Proteins; Macrolides; Molecular Sequence Data; Multidrug Resistance-Associated Proteins; Mutagenesis, Site-Directed; Sequence Homology, Amino Acid | 2009 |
Antimicrobial susceptibility of Mycoplasma pneumoniae isolates and molecular analysis of macrolide-resistant strains from Shanghai, China.
Topics: Adhesins, Bacterial; Anti-Bacterial Agents; Child; China; Drug Resistance, Bacterial; Genes, rRNA; Humans; Macrolides; Microbial Sensitivity Tests; Mutation; Mycoplasma pneumoniae; Pneumonia, Mycoplasma; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; Respiratory Tract Infections; RNA, Ribosomal, 23S; Sequence Analysis, DNA | 2009 |
Comparative antipneumococcal activities of sulopenem and other drugs.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; Lactams; Microbial Sensitivity Tests; Penicillin-Binding Proteins; Streptococcus pneumoniae | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
Topics: Anti-Bacterial Agents; Azepines; Bacteria, Anaerobic; Drug Resistance, Bacterial; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Microbial Sensitivity Tests | 2009 |
In vitro activity of a new quinoline derivative, ER-2, against clinical isolates of Mycoplasma pneumoniae and Mycoplasma hominis.
Topics: Anti-Bacterial Agents; Humans; Microbial Sensitivity Tests; Molecular Structure; Mycoplasma hominis; Mycoplasma pneumoniae; Pneumonia, Mycoplasma; Quinolines | 2009 |
Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR.
Topics: Microbial Sensitivity Tests; Mycoplasma genitalium; Polymerase Chain Reaction | 2009 |
In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms.
Topics: Anti-Bacterial Agents; Drug Resistance, Bacterial; Macrolides; Microbial Sensitivity Tests; Penicillin G; Streptococcus pneumoniae; Streptococcus pyogenes; Triazoles | 2010 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Antimicrobial susceptibilities of multidrug-resistant Campylobacter jejuni and C. coli strains: in vitro activities of 20 antimicrobial agents.
Topics: Anti-Bacterial Agents; Campylobacter coli; Campylobacter Infections; Campylobacter jejuni; Carbapenems; Drug Resistance, Multiple, Bacterial; Erythromycin; Feces; Finland; Humans; Macrolides; Microbial Sensitivity Tests; Minocycline; Tigecycline | 2010 |
Distribution of serotypes, genotypes, and resistance determinants among macrolide-resistant Streptococcus pneumoniae isolates.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Child, Preschool; DNA Transposable Elements; Drug Resistance, Bacterial; Erythromycin; Genotype; Humans; Macrolides; Microbial Sensitivity Tests; New South Wales; Pneumococcal Infections; Serotyping; Streptococcus pneumoniae | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Design, synthesis, and biological evaluations of novel 7-[7-amino-7-methyl-5-azaspiro[2.4]heptan-5-yl]-8-methoxyquinolines with potent antibacterial activity against respiratory pathogens.
Topics: Animals; Anti-Bacterial Agents; Drug Design; Fluoroquinolones; Haemophilus influenzae; Male; Mice; Microbial Sensitivity Tests; Quinolones; Rats; Respiratory Tract Infections; Spiro Compounds; Staphylococcus aureus; Streptococcus pneumoniae | 2013 |
Comparative in-vitro activity of moxifloxacin, minocycline and azithromycin against Chlamydia spp.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Azithromycin; Chlamydia; Chlamydia trachomatis; Chlamydophila pneumoniae; Chlamydophila psittaci; Fluoroquinolones; Humans; Male; Microbial Sensitivity Tests; Minocycline; Moxifloxacin; Quinolines | 1999 |
Activities of antimicrobial agents against intracellular pneumococci.
Topics: Anti-Bacterial Agents; Aza Compounds; Azithromycin; Fluoroquinolones; Gentamicins; Humans; Ketolides; Levofloxacin; Macrolides; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Penicillin G; Quinolines; Rifampin; Streptococcus pneumoniae; Tumor Cells, Cultured | 2000 |
Activity of moxifloxacin by itself and in combination with ethambutol, rifabutin, and azithromycin in vitro and in vivo against Mycobacterium avium.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Antitubercular Agents; Aza Compounds; Azithromycin; Drug Interactions; Drug Therapy, Combination; Ethambutol; Female; Fluoroquinolones; Macrophages; Mice; Mice, Inbred C57BL; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium avium Complex; Mycobacterium avium-intracellulare Infection; Quinolines; Rifabutin | 2001 |
Comparative in vitro activity of moxifloxacin by E-test against Streptococcus pyogenes.
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Azithromycin; Clarithromycin; Drug Resistance, Microbial; Fluoroquinolones; Humans; Lactams; Microbial Sensitivity Tests; Moxifloxacin; Quinolines; Streptococcus pyogenes | 2001 |
Effect of antipyretic agents on uptake, transport, and release of antimicrobial agents by human polymorphonuclear leukocytes.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Bacterial Agents; Aspirin; Aza Compounds; Azithromycin; Biological Transport; Cell Movement; Fluoroquinolones; Humans; Ibuprofen; Microbial Sensitivity Tests; Moxifloxacin; Neutrophils; Quinolines | 2002 |
Comparative intracellular (THP-1 macrophage) and extracellular activities of beta-lactams, azithromycin, gentamicin, and fluoroquinolones against Listeria monocytogenes at clinically relevant concentrations.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Azithromycin; beta-Lactams; Ciprofloxacin; Fluoroquinolones; Gentamicins; Humans; Listeria monocytogenes; Macrophages; Microbial Sensitivity Tests; Moxifloxacin; Quinolines | 2002 |
Activity of beta-lactams (ampicillin, meropenem), gentamicin, azithromycin and moxifloxacin against intracellular Listeria monocytogenes in a 24 h THP-1 human macrophage model.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Azithromycin; Cells, Cultured; Colony Count, Microbial; Culture Media; Fluoroquinolones; Gentamicins; Humans; Listeria monocytogenes; Macrophages; Moxifloxacin; Quinolines | 2003 |
Quantitative analysis of gentamicin, azithromycin, telithromycin, ciprofloxacin, moxifloxacin, and oritavancin (LY333328) activities against intracellular Staphylococcus aureus in mouse J774 macrophages.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Azithromycin; Ciprofloxacin; Fluoroquinolones; Gentamicins; Glycopeptides; Lipoglycopeptides; Lymphoma, Large B-Cell, Diffuse; Macrophages; Mice; Microbial Sensitivity Tests; Microscopy, Electron; Moxifloxacin; Quinolines; Staphylococcal Infections; Staphylococcus aureus; Tumor Cells, Cultured | 2003 |
Susceptibility testing of Singapore strains of Mycoplasma hominis to tetracycline, gatifloxacin, moxifloxacin, ciprofloxacin, clindamycin, and azithromycin by the Etest method.
Topics: Anti-Bacterial Agents; Aza Compounds; Azithromycin; Ciprofloxacin; Clindamycin; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Microbial Sensitivity Tests; Moxifloxacin; Mycoplasma hominis; Quinolines; Sampling Studies; Sensitivity and Specificity; Singapore; Tetracycline | 2004 |
Comparative in vitro activities of three new quinolones and azithromycin against aerobic pathogens causing respiratory tract and abdominal wound infections.
Topics: Abdominal Injuries; Anti-Bacterial Agents; Aza Compounds; Azithromycin; Bacteria, Aerobic; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Methicillin Resistance; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines; Quinolones; Respiratory Tract Infections; Wound Infection | 2004 |
New real-time PCR-based method for in vitro susceptibility testing of Anaplasma phagocytophilum against antimicrobial agents.
Topics: Ampicillin; Anaplasma phagocytophilum; Anti-Bacterial Agents; Aza Compounds; Azithromycin; DNA, Bacterial; DNA, Ribosomal; Doxycycline; Fluoroquinolones; Genes, rRNA; Gentamicins; Ketolides; Microbial Sensitivity Tests; Moxifloxacin; Polymerase Chain Reaction; Quinolines; Reproducibility of Results; RNA, Bacterial; RNA, Ribosomal, 16S; Sensitivity and Specificity | 2004 |
Bactericidal activity of moxifloxacin against multidrug-resistant Streptoccocus pneumoniae at clinically achievable serum and epithelial lining fluid concentrations compared with three other antimicrobials.
Topics: Anti-Bacterial Agents; Aza Compounds; Azithromycin; Drug Resistance, Bacterial; Drug Resistance, Multiple; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines; Streptococcus pneumoniae | 2004 |
A subinhibitory concentration of clarithromycin inhibits Mycobacterium avium biofilm formation.
Topics: Acquired Immunodeficiency Syndrome; Anti-Bacterial Agents; Aza Compounds; Azithromycin; Biofilms; Clarithromycin; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Microscopy, Electron, Scanning; Moxifloxacin; Mycobacterium avium Complex; Mycobacterium avium-intracellulare Infection; Quinolines | 2004 |
In vitro selection of resistance to clarithromycin in Streptococcus pneumoniae clinical isolates.
Topics: Amoxicillin; Aza Compounds; Azithromycin; Clarithromycin; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines; Sampling Studies; Sensitivity and Specificity; Streptococcus pneumoniae | 2005 |
Moxifloxacin and azithromycin but not amoxicillin protect human respiratory epithelial cells against streptococcus pneumoniae in vitro when administered up to 6 hours after challenge.
Topics: Amoxicillin; Anti-Bacterial Agents; Aza Compounds; Azithromycin; Epithelial Cells; Fluoroquinolones; Humans; Moxifloxacin; Quinolines; Streptococcus pneumoniae | 2005 |
The effect of treatment with moxifloxacin or azithromycin on acute bacterial rhinosinusitis in mice.
Topics: Acute Disease; Animals; Anti-Bacterial Agents; Aza Compounds; Azithromycin; CD11b Antigen; CD4 Antigens; CD8 Antigens; Disease Models, Animal; Female; Fluoroquinolones; Male; Mice; Mice, Inbred C57BL; Moxifloxacin; Pneumococcal Infections; Quinolines; Rhinitis; Sinusitis; Streptococcus pneumoniae | 2006 |
Activities of ceftobiprole, a novel broad-spectrum cephalosporin, against Haemophilus influenzae and Moraxella catarrhalis.
Topics: Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Aza Compounds; Azithromycin; beta-Lactamases; Cefpodoxime; Ceftizoxime; Ceftriaxone; Cephalosporins; Colony Count, Microbial; Drug Resistance, Bacterial; Fluoroquinolones; Haemophilus influenzae; Humans; In Vitro Techniques; Ketolides; Microbial Sensitivity Tests; Moraxella catarrhalis; Moxifloxacin; Quinolines; Selection, Genetic | 2006 |
Antipneumococcal activity of DW-224a, a new quinolone, compared to those of eight other agents.
Topics: Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Azithromycin; Cefuroxime; Ciprofloxacin; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Genes, Bacterial; Levofloxacin; Microbial Sensitivity Tests; Molecular Structure; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines; Streptococcus pneumoniae | 2006 |
A pharmacodynamic approach to antimicrobial activity in serum and epithelial lining fluid against in vivo-selected Streptococcus pneumoniae mutants and association with clinical failure in pneumonia.
Topics: Anti-Bacterial Agents; Aza Compounds; Azithromycin; Community-Acquired Infections; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Models, Biological; Moxifloxacin; Mutation; Ofloxacin; Pneumonia, Pneumococcal; Quinolines; Serum Bactericidal Test; Streptococcus pneumoniae | 2006 |
Azithromycin failure in Mycoplasma genitalium urethritis.
Topics: Adult; Anti-Bacterial Agents; Aza Compounds; Azithromycin; Female; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Mycoplasma genitalium; Mycoplasma Infections; Quinolines; Treatment Failure; Urethritis | 2006 |
Increased polymorphonuclear leukocyte respiratory burst function in type 2 diabetes.
Topics: Anti-Bacterial Agents; Aza Compounds; Azithromycin; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Fluoroquinolones; Humans; Male; Mexican Americans; Moxifloxacin; Neutrophils; Ofloxacin; Protein Kinase C; Quinolines; Respiratory Burst; Superoxides; Tetradecanoylphorbol Acetate; Zymosan | 2007 |
Moxifloxacin but not ciprofloxacin or azithromycin selectively inhibits IL-8, IL-6, ERK1/2, JNK, and NF-kappaB activation in a cystic fibrosis epithelial cell line.
Topics: Anti-Infective Agents; Aza Compounds; Azithromycin; Bronchi; Cell Line; Ciprofloxacin; Cystic Fibrosis; Epithelial Cells; Extracellular Signal-Regulated MAP Kinases; Fluoroquinolones; Humans; Interleukin-1beta; Interleukin-6; Interleukin-8; JNK Mitogen-Activated Protein Kinases; Lipopolysaccharides; Moxifloxacin; NF-kappa B; Phosphorylation; Quinolines; Tumor Necrosis Factor-alpha | 2007 |
No proarrhythmic properties of the antibiotics Moxifloxacin or Azithromycin in anaesthetized dogs with chronic-AV block.
Topics: Anesthesia; Animals; Anti-Arrhythmia Agents; Anti-Bacterial Agents; Arrhythmias, Cardiac; Aza Compounds; Azithromycin; Dogs; Dose-Response Relationship, Drug; Electric Stimulation; Electroencephalography; Electrophysiology; Fluoroquinolones; Heart Block; Heart Rate; Long QT Syndrome; Moxifloxacin; Phenethylamines; Quinolines; Sulfonamides; Torsades de Pointes | 2006 |
Central venous catheter-related Streptomyces septic thrombosis.
Topics: Aged; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Azithromycin; Catheterization, Central Venous; Fluoroquinolones; Humans; Male; Minocycline; Moxifloxacin; Quinolines; Sepsis; Streptomyces; Treatment Outcome; Venous Thrombosis | 2007 |
Antibiotic resistance testing of the total implant-associated micro-flora and its pure isolates.
Topics: Ampicillin; Anti-Bacterial Agents; Aza Compounds; Azithromycin; Bacteria, Anaerobic; Dental Implants; Dental Plaque; Dose-Response Relationship, Drug; Drug Combinations; Drug Resistance, Bacterial; Female; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Cocci; Gram-Positive Rods; Humans; In Vitro Techniques; Male; Microbial Sensitivity Tests; Moxifloxacin; Penicillin G; Quinolines; Sulbactam | 2007 |
Comparative activities of antibiotics against intracellular non-typeable Haemophilus influenzae.
Topics: Adolescent; Adult; Ampicillin; Anti-Bacterial Agents; Aza Compounds; Azithromycin; Bacterial Typing Techniques; Bronchi; Cells, Cultured; Ciprofloxacin; Epithelial Cells; Female; Fluoroquinolones; Haemophilus influenzae; Humans; Ketolides; Male; Moxifloxacin; Quinolines | 2007 |
Emergency department drug orders: does drug storage location make a difference?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Infective Agents; Anti-Ulcer Agents; Aza Compounds; Azithromycin; Drug Storage; Drug Utilization; Emergency Service, Hospital; Fluoroquinolones; Hospitals, Urban; Humans; Injections; Medical Order Entry Systems; Medication Systems, Hospital; Moxifloxacin; Pantoprazole; Pharmacies; Quinolines; Retrospective Studies | 2007 |
Susceptibility of oral obligate anaerobes to telithromycin, moxifloxacin and a number of commonly used antibacterials.
Topics: Adult; Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Azithromycin; Blood; Clindamycin; Culture Media; Drug Resistance, Bacterial; Fluoroquinolones; Gram-Negative Anaerobic Bacteria; Hemin; Humans; Ketolides; Metronidazole; Microbial Sensitivity Tests; Moxifloxacin; Penicillin Resistance; Periodontitis; Quinolines; Saliva; Vitamin K | 2007 |
Azithromycin and moxifloxacin for microbiological cure of Mycoplasma genitalium infection: an open study.
Topics: Anti-Bacterial Agents; Aza Compounds; Azithromycin; Female; Fluoroquinolones; Humans; Male; Moxifloxacin; Mycoplasma genitalium; Mycoplasma Infections; Quinolines; Treatment Outcome | 2008 |
"My foot hurts": a flare of rheumatoid arthritis?
Topics: Arthritis, Rheumatoid; Aza Compounds; Azithromycin; Drug Therapy, Combination; Fluoroquinolones; Humans; Legionella longbeachae; Legionellosis; Male; Middle Aged; Moxifloxacin; Neutropenia; Osteomyelitis; Quinolines; Steroids | 2009 |
Moxifloxacin associated vanishing bile duct syndrome.
Topics: Aged, 80 and over; Anti-Infective Agents; Aza Compounds; Azithromycin; Bile Duct Diseases; Ceftriaxone; Fluoroquinolones; Humans; Male; Moxifloxacin; Quinolines; Syndrome | 2010 |
Impact of a low-oxygen environment on the efficacy of antimicrobials against intracellular Chlamydia trachomatis.
Topics: Anti-Infective Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Aza Compounds; Azithromycin; Cell Hypoxia; Cell Line; Chlamydia trachomatis; Doxycycline; Female; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Moxifloxacin; Polymerase Chain Reaction; Quinolines; Rifampin | 2011 |
Antibiotic susceptibility of cocultures in polymicrobial infections such as peri-implantitis or periodontitis: an in vitro model.
Topics: Acetamides; Actinobacillus Infections; Aggregatibacter actinomycetemcomitans; Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Ampicillin; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Azithromycin; Capnocytophaga; Coculture Techniques; Coinfection; Drug Resistance, Bacterial; Fluoroquinolones; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Humans; Linezolid; Metronidazole; Microbial Interactions; Minocycline; Moxifloxacin; Oxazolidinones; Penicillin G; Peptostreptococcus; Peri-Implantitis; Periodontitis; Quinolines; Sulbactam | 2011 |
Mycobacterium bolletii/Mycobacterium massiliense furunculosis associated with pedicure footbaths: a report of 3 cases.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Aza Compounds; Azithromycin; Bacterial Proteins; Baths; Chaperonin 60; Cosmetic Techniques; Female; Fluoroquinolones; Foot Dermatoses; Furunculosis; Humans; Moxifloxacin; Mycobacterium; Mycobacterium Infections; Quinolines; Treatment Outcome; Young Adult | 2011 |
[Regional difference of antibiotic resistance of helicobacter pylori strains in Korea].
Topics: Amoxicillin; Anti-Bacterial Agents; Aza Compounds; Azithromycin; Ciprofloxacin; Clarithromycin; Drug Resistance, Bacterial; Female; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Ofloxacin; Quinolines; Republic of Korea; Tetracycline | 2011 |
Susceptibility of Ureaplasma urealyticum to tetracycline, doxycycline, erythromycin, roxithromycin, clarithromycin, azithromycin, levofloxacin and moxifloxacin.
Topics: Anti-Bacterial Agents; Aza Compounds; Azithromycin; Clarithromycin; Dose-Response Relationship, Drug; Doxycycline; Erythromycin; Female; Fluoroquinolones; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines; Reproducibility of Results; Roxithromycin; Tetracycline; Time Factors; Ureaplasma Infections; Ureaplasma urealyticum | 2011 |
Antimicrobial efficacies of several antibiotics against uterine cervicitis caused by Mycoplasma genitalium.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Aza Compounds; Azithromycin; Female; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Moxifloxacin; Mycoplasma genitalium; Mycoplasma Infections; Polymerase Chain Reaction; Quinolines; Retrospective Studies; Uterine Cervicitis | 2012 |
Mycoplasma genitalium: should we treat and how?
Topics: Anti-Bacterial Agents; Aza Compounds; Azithromycin; Doxycycline; Drug Resistance, Bacterial; Female; Fluoroquinolones; Humans; Infertility, Female; Male; Moxifloxacin; Mycoplasma genitalium; Mycoplasma Infections; Pelvic Inflammatory Disease; Pregnancy; Pregnancy, Ectopic; Quinolines; Treatment Outcome; Urethritis; Uterine Cervicitis | 2011 |
Susceptibility of methicillin-resistant Staphylococci clinical isolates to netilmicin and other antibiotics commonly used in ophthalmic therapy.
Topics: Anti-Bacterial Agents; Aza Compounds; Azithromycin; Chloramphenicol; Drug Resistance; Eye Infections, Bacterial; Fluoroquinolones; Humans; Levofloxacin; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Moxifloxacin; Netilmicin; Quinolines; Staphylococcus epidermidis; Tobramycin; Vancomycin | 2013 |
Endogenous lipoid pneumonia associated with Legionella pneumophila serogroup 1.
Topics: Adult; Anti-Bacterial Agents; Aza Compounds; Azithromycin; Female; Fluoroquinolones; Humans; Legionella pneumophila; Legionnaires' Disease; Moxifloxacin; Pneumonia, Lipid; Quinolines; Treatment Outcome | 2013 |
Multiple resistance to betalactam antibiotics, azithromycin or moxifloxacin in implant associated bacteria.
Topics: Aza Compounds; Azithromycin; Bacteria; beta-Lactams; Dental Implants; Drug Resistance, Microbial; Drug Resistance, Multiple; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Moxifloxacin; Quinolines | 2013 |
Bubonic lymphogranuloma venereum with multidrug treatment failure.
Topics: Anti-Bacterial Agents; Aza Compounds; Azithromycin; Chlamydia trachomatis; Doxycycline; Fluoroquinolones; Homosexuality, Male; Humans; Lymphogranuloma Venereum; Male; Middle Aged; Moxifloxacin; Multilocus Sequence Typing; Proctitis; Quinolines; Real-Time Polymerase Chain Reaction; Treatment Failure | 2014 |
In vitro activity of the new fluoroketolide solithromycin (CEM-101) against macrolide-resistant and -susceptible Mycoplasma genitalium strains.
Topics: Anti-Bacterial Agents; Azithromycin; DNA, Bacterial; DNA, Ribosomal; Doxycycline; Drug Resistance, Bacterial; Fluoroquinolones; Gonorrhea; Humans; Macrolides; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Mycoplasma genitalium; Mycoplasma Infections; Neisseria gonorrhoeae; Triazoles | 2014 |
Fluoroquinolone- and ceftriaxone-based therapy of community-acquired pneumonia in hospitalized patients: the risk of subsequent isolation of multidrug-resistant organisms.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Azithromycin; Bacteria; Ceftriaxone; Cohort Studies; Community-Acquired Infections; Drug Resistance, Multiple, Bacterial; Female; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Pneumonia, Bacterial; Retrospective Studies; Risk Assessment; Young Adult | 2014 |
Effect of prophylactic antibiotics on polyacrylamide gel safety in facial augmentation.
Topics: Acrylic Resins; Adolescent; Adult; Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Azithromycin; Bacterial Infections; Biofilms; Cosmetic Techniques; Face; Female; Fluoroquinolones; Humans; Incidence; Inflammation; Injections; Male; Middle Aged; Moxifloxacin; Retrospective Studies; Young Adult | 2014 |
Diagnosis and antimicrobial treatment of Mycoplasma genitalium infection: sobering thoughts.
Topics: Anti-Bacterial Agents; Azithromycin; Coinfection; Doxycycline; Drug Resistance, Bacterial; Female; Fluoroquinolones; HIV Infections; Humans; Male; Moxifloxacin; Mycoplasma genitalium; Mycoplasma Infections; Urethritis | 2014 |
Antimycobacterial drugs modulate immunopathogenic matrix metalloproteinases in a cellular model of pulmonary tuberculosis.
Topics: Antitubercular Agents; Azithromycin; Bronchoalveolar Lavage Fluid; Epithelial Cells; Fibroblasts; Fluoroquinolones; Humans; Isoenzymes; Isoniazid; Lung; Matrix Metalloproteinases; Models, Biological; Moxifloxacin; Mycobacterium tuberculosis; Primary Cell Culture; Rifampin; Stromal Cells; Tuberculosis, Pulmonary | 2014 |
Risks of cardiac arrhythmia and mortality among patients using new-generation macrolides, fluoroquinolones, and β-lactam/β-lactamase inhibitors: a Taiwanese nationwide study.
Topics: Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Arrhythmias, Cardiac; Azithromycin; beta-Lactamase Inhibitors; Cardiovascular Diseases; Ciprofloxacin; Clarithromycin; Comorbidity; Female; Fluoroquinolones; Humans; Levofloxacin; Logistic Models; Male; Moxifloxacin; Risk; Taiwan | 2015 |
Macrolide resistance and azithromycin failure in a Mycoplasma genitalium-infected cohort and response of azithromycin failures to alternative antibiotic regimens.
Topics: Adult; Anti-Bacterial Agents; Azithromycin; Drug Resistance, Bacterial; Female; Fluoroquinolones; Humans; Macrolides; Male; Middle Aged; Moxifloxacin; Mycoplasma genitalium; Mycoplasma Infections; Pristinamycin; Treatment Failure; Young Adult | 2015 |
Spontaneous Regression of Untreatable Mycoplasma genitalium Urethritis.
Topics: Anti-Bacterial Agents; Azithromycin; Doxycycline; Fluoroquinolones; Humans; Male; Middle Aged; Moxifloxacin; Mycoplasma genitalium; Mycoplasma Infections; Remission, Spontaneous; Time Factors; Treatment Failure; Urethritis | 2015 |
Efficacy of postexposure therapy against glanders in mice.
Topics: Aerosols; Animals; Anti-Bacterial Agents; Azithromycin; Bacterial Vaccines; Burkholderia mallei; Combined Modality Therapy; Female; Fluoroquinolones; Glanders; Mice; Mice, Inbred BALB C; Moxifloxacin; Spleen; Trimethoprim, Sulfamethoxazole Drug Combination; Vaccination | 2015 |
Pulmonary mycobacterial spindle cell pseudotumor in a lung transplant patient: progression without therapy and response to therapy.
Topics: Aged; Anti-Bacterial Agents; Azithromycin; Disease Progression; Ethambutol; Female; Fluoroquinolones; Humans; Immunocompromised Host; Lung; Lung Transplantation; Moxifloxacin; Mycobacterium avium Complex; Mycobacterium avium-intracellulare Infection; Treatment Outcome | 2015 |
Factors associated with antibiotic misuse in outpatient treatment for upper respiratory tract infections.
Topics: Ambulatory Care; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Azithromycin; Centers for Disease Control and Prevention, U.S.; Drug Utilization; Female; Fluoroquinolones; Humans; Inappropriate Prescribing; Male; Middle Aged; Moxifloxacin; Multivariate Analysis; Outpatients; Practice Patterns, Physicians'; Respiratory Tract Infections; Retrospective Studies; United States | 2015 |
2015 UK National Guideline on the management of non-gonococcal urethritis.
Topics: Anti-Bacterial Agents; Azithromycin; Chlamydia Infections; Chlamydia trachomatis; Disease Management; Doxycycline; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Male; Metronidazole; Moxifloxacin; Mycoplasma genitalium; Mycoplasma Infections; Practice Guidelines as Topic; United Kingdom; Urethritis | 2016 |
Postcesarean section wound infection caused by Mycobacterium massiliense.
Topics: Adult; Anti-Bacterial Agents; Azithromycin; Bacterial Proteins; Cesarean Section; Chaperonin 60; Cilastatin; Cilastatin, Imipenem Drug Combination; Clarithromycin; Drug Combinations; Electrophoresis, Gel, Pulsed-Field; Female; Fluoroquinolones; Humans; Imipenem; Methyltransferases; Microbial Sensitivity Tests; Molecular Typing; Moxifloxacin; Mycobacterium Infections; Nontuberculous Mycobacteria; Pregnancy; Surgical Wound Infection; Teicoplanin | 2016 |
2016 European guideline on the management of non-gonococcal urethritis.
Topics: Anti-Bacterial Agents; Azithromycin; Chlamydia trachomatis; Doxycycline; Drug Resistance, Bacterial; Fluoroquinolones; Guidelines as Topic; Humans; Metronidazole; Moxifloxacin; Mycoplasma genitalium; Urethritis | 2016 |
Mycoplasma genitalium in Toronto, Ont: Estimates of prevalence and macrolide resistance.
Topics: Adult; Anti-Bacterial Agents; Azithromycin; Cross-Sectional Studies; Doxycycline; Drug Resistance, Bacterial; Female; Fluoroquinolones; Humans; Macrolides; Male; Middle Aged; Moxifloxacin; Mycoplasma genitalium; Mycoplasma Infections; Ontario; Prospective Studies; Sex Factors; Treatment Outcome; Young Adult | 2016 |
[Mycoplasma genitalium].
Topics: Anti-Bacterial Agents; Azithromycin; Endometritis; Female; Fluoroquinolones; Humans; Male; Moxifloxacin; Mycoplasma genitalium; Mycoplasma Infections; Salpingitis; Urethritis; Uterine Cervicitis; Vaginosis, Bacterial | 2016 |
In Vitro Activities of Lefamulin and Other Antimicrobial Agents against Macrolide-Susceptible and Macrolide-Resistant Mycoplasma pneumoniae from the United States, Europe, and China.
Topics: Anti-Bacterial Agents; Azithromycin; China; Diterpenes; Doxycycline; Drug Resistance, Bacterial; Erythromycin; Europe; Fluoroquinolones; Macrolides; Microbial Sensitivity Tests; Moxifloxacin; Mycoplasma pneumoniae; Pleuromutilins; Polycyclic Compounds; United States | 2017 |
Interleukin-1α induced release of interleukin-8 by human bronchial epithelial cells in vitro: assessing mechanisms and possible treatment options.
Topics: Acetates; Acetylcysteine; Aminopyridines; Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Azithromycin; Benzamides; Bronchi; Cell Line; Cyclopropanes; Dapsone; Dexamethasone; Dose-Response Relationship, Drug; Epithelial Cells; Fluoroquinolones; Humans; Interleukin-1alpha; Interleukin-8; MAP Kinase Signaling System; Moxifloxacin; Neutrophils; Phosphorylation; Pyridones; Quinolines; Sulfides; Theophylline; Treatment Outcome | 2017 |
Clinical significance of QT-prolonging drug use in patients with MDR-TB or NTM disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Azithromycin; Child; Clarithromycin; Clofazimine; Diarylquinolines; Female; Fluoroquinolones; Follow-Up Studies; Humans; Lost to Follow-Up; Macrolides; Male; Middle Aged; Moxifloxacin; Mycobacterium Infections, Nontuberculous; Mycobacterium tuberculosis; Nitroimidazoles; Nontuberculous Mycobacteria; Oxazoles; Retrospective Studies; Tuberculosis, Multidrug-Resistant; Young Adult | 2017 |
A 'shock and awe' thioridazine and moxifloxacin combination-based regimen for pulmonary Mycobacterium avium-intracellulare complex disease.
Topics: Anti-Bacterial Agents; Antipsychotic Agents; Azithromycin; Drug Therapy, Combination; Ethambutol; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Models, Biological; Monocytes; Moxifloxacin; Mycobacterium avium Complex; Thioridazine; THP-1 Cells | 2017 |
Appraisal of the cardiovascular risks of azithromycin: an observational analysis.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Azithromycin; Cardiovascular Diseases; Clarithromycin; Female; Humans; Levofloxacin; Male; Middle Aged; Moxifloxacin; Retrospective Studies; Risk Factors; Young Adult | 2017 |
Mycoplasma-associated multidrug resistance of hepatocarcinoma cells requires the interaction of P37 and Annexin A2.
Topics: Adaptor Proteins, Signal Transducing; Annexin A2; Anti-Bacterial Agents; Antineoplastic Agents; Azithromycin; Carcinoma, Hepatocellular; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fluoroquinolones; Gemcitabine; Humans; Liver Neoplasms; Mitoxantrone; Moxifloxacin; Mycoplasma hyorhinis; Protein Binding; Real-Time Polymerase Chain Reaction | 2017 |
Cellular Pharmacokinetics and Intracellular Activity of Gepotidacin against Staphylococcus aureus Isolates with Different Resistance Phenotypes in Models of Cultured Phagocytic Cells.
Topics: Acenaphthenes; Anti-Bacterial Agents; Azithromycin; Cell Line; Daptomycin; Heterocyclic Compounds, 3-Ring; Humans; Linezolid; Macrolides; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Moxifloxacin; Oxacillin; Phagocytes; Staphylococcus aureus; THP-1 Cells; Vancomycin | 2018 |
Clinical Characteristics of Anorectal Mycoplasma genitalium Infection and Microbial Cure in Men Who Have Sex With Men.
Topics: Adult; Anti-Infective Agents; Azithromycin; Chlamydia trachomatis; Coinfection; Gonorrhea; Homosexuality, Male; Humans; Male; Moxifloxacin; Mycoplasma genitalium; Mycoplasma Infections; Neisseria gonorrhoeae; Pristinamycin; Proctitis; Rectal Diseases; Sexual and Gender Minorities; Sexual Behavior; Victoria; Young Adult | 2018 |
Clinical characteristics from co-infection with avian influenza A H7N9 and Mycoplasma pneumoniae: a case report.
Topics: Aged, 80 and over; Anti-Bacterial Agents; Azithromycin; Coinfection; Female; Fluoroquinolones; Humans; Immunoglobulins; Influenza A Virus, H7N9 Subtype; Influenza, Human; Methylprednisolone; Moxifloxacin; Mycoplasma pneumoniae; Oseltamivir; Pneumonia, Mycoplasma | 2018 |
Topics: Anti-Bacterial Agents; Azithromycin; Cell Line; Chlamydial Pneumonia; Chlamydophila pneumoniae; Doxycycline; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Tetracyclines | 2019 |
Topics: Anti-Bacterial Agents; Azithromycin; Canada; Drug Resistance, Bacterial; Female; Fluoroquinolones; Health Surveys; Humans; Male; Moxifloxacin; Mycoplasma genitalium; Mycoplasma Infections; Practice Guidelines as Topic; Prevalence; Sexually Transmitted Diseases, Bacterial | 2019 |
Prevalence of genital Mycoplasma and response to eradication treatment in patients undergoing assisted reproductive techniques.
Topics: Adult; Anti-Bacterial Agents; Azithromycin; Clindamycin; Doxycycline; Embryo Implantation; Female; Genital Diseases, Female; Genital Diseases, Male; Humans; Levofloxacin; Male; Middle Aged; Moxifloxacin; Mycoplasma hominis; Mycoplasma Infections; Prevalence; Real-Time Polymerase Chain Reaction; Reproductive Techniques, Assisted; Semen Analysis; Sex Factors; Treatment Outcome; Ureaplasma Infections; Ureaplasma urealyticum; Young Adult | 2019 |
Effects of antibiotics and antiseptics on conjunctival bacterial flora in patients undergoing intravitreal injections.
Topics: Anti-Bacterial Agents; Anti-Infective Agents, Local; Azithromycin; Conjunctiva; Humans; Intravitreal Injections; Moxifloxacin; Povidone-Iodine | 2019 |
Resistance-Guided Antimicrobial Therapy Using Doxycycline-Moxifloxacin and Doxycycline-2.5 g Azithromycin for the Treatment of Mycoplasma genitalium Infection: Efficacy and Tolerability.
Topics: Anti-Bacterial Agents; Australia; Azithromycin; Doxycycline; Drug Resistance, Bacterial; Female; Homosexuality, Male; Humans; Macrolides; Male; Moxifloxacin; Mycoplasma genitalium; Mycoplasma Infections; Sexual and Gender Minorities | 2020 |
Resistance-Guided Therapy for Mycoplasma genitalium Infections.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Doxycycline; Drug Resistance, Bacterial; Humans; Moxifloxacin; Mycoplasma genitalium; Mycoplasma Infections | 2020 |
High rates of treatment failure for
Topics: Adolescent; Adult; Anti-Bacterial Agents; Azithromycin; Doxycycline; England; Female; Humans; Male; Mass Screening; Middle Aged; Moxifloxacin; Mycoplasma genitalium; Mycoplasma Infections; Reproductive Health Services; Treatment Outcome; Urethritis | 2020 |
Macrolide and fluoroquinolone resistance of
Topics: Adult; Anti-Bacterial Agents; Azithromycin; DNA Topoisomerase IV; Drug Resistance, Bacterial; Female; Fluoroquinolones; Heterosexuality; Homosexuality, Male; Humans; Macrolides; Male; Moxifloxacin; Mutation; Mycoplasma genitalium; RNA, Ribosomal, 23S; Sequence Analysis, DNA; Spain; Young Adult | 2021 |
Azithromycin, minocycline, moxifloxacin and spectinomycin failure in a case with persistent
Topics: Anti-Bacterial Agents; Azithromycin; DNA Gyrase; DNA, Bacterial; Humans; Middle Aged; Minocycline; Moxifloxacin; Mycoplasma genitalium; Mycoplasma Infections; RNA, Ribosomal, 23S; Sequence Analysis, DNA; Spectinomycin; Treatment Failure; Urethritis | 2020 |
In vitro evaluation of antimicrobial resistance selection in Neisseria gonorrhoeae.
Topics: Anti-Bacterial Agents; Azithromycin; Ceftriaxone; Ciprofloxacin; Doxycycline; Drug Resistance, Multiple, Bacterial; Ertapenem; Gentamicins; Gonorrhea; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Neisseria gonorrhoeae | 2021 |
Combination Therapy for Mycoplasma genitalium, and New Insights Into the Utility of parC Mutant Detection to Improve Cure.
Topics: Anti-Bacterial Agents; Azithromycin; Doxycycline; Drug Resistance, Bacterial; Humans; Macrolides; Moxifloxacin; Mycoplasma genitalium; Mycoplasma Infections | 2022 |
2021 European guideline on the management of Mycoplasma genitalium infections.
Topics: Anti-Bacterial Agents; Azithromycin; Doxycycline; Drug Resistance, Bacterial; Dysuria; Female; Humans; Macrolides; Male; Moxifloxacin; Mycoplasma genitalium; Mycoplasma Infections; Urethritis | 2022 |
Association between initiation of fluoroquinolones and hospital admission or emergency department visit for suicidality: population based cohort study.
Topics: Adult; Anti-Bacterial Agents; Azithromycin; Ciprofloxacin; Cohort Studies; Emergency Service, Hospital; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Hospitals; Humans; Levofloxacin; Moxifloxacin; Norfloxacin; Retrospective Studies; Suicidal Ideation; Suicide; Trimethoprim, Sulfamethoxazole Drug Combination; Urinary Tract Infections | 2022 |
Azithromycin and moxifloxacin resistance-associated mutations in Mycoplasma genitalium, in the Region of Murcia, by a commercial PCR assay.
Topics: Azithromycin; Moxifloxacin; Mutation; Mycoplasma genitalium; Polymerase Chain Reaction | 2023 |
Topics: Anti-Bacterial Agents; Azithromycin; Drug Resistance, Bacterial; Fluoroquinolones; Genitalia; Homosexuality, Male; Humans; Macrolides; Male; Moxifloxacin; Mutation; Mycoplasma genitalium; Prevalence; RNA, Ribosomal, 23S; Sexual and Gender Minorities; Sexually Transmitted Diseases | 2023 |
Safety study of moxifloxacin in children with severe refractory Mycoplasma pneumoniae pneumonia.
Topics: Anti-Bacterial Agents; Azithromycin; Child; Drug Resistance, Bacterial; Humans; Moxifloxacin; Mycoplasma pneumoniae; Pneumonia, Mycoplasma; Retrospective Studies | 2023 |
[The problem of formation of new risks of medicinal resistance of patients with tuberculosis in condition of active use of antibiotics by population under COVID-19].
Topics: Anti-Infective Agents; Antitubercular Agents; Azithromycin; COVID-19; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Levofloxacin; Moxifloxacin; Mycobacterium tuberculosis; Pandemics; Quinolones; Tuberculosis | 2023 |
The Relationship of Comorbid Diseases and Empirical Antibiotic Usage with Superinfection in COVID-19 Patients.
Topics: Anti-Bacterial Agents; Azithromycin; COVID-19; Humans; Moxifloxacin; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Superinfection | 2023 |